<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790647</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000618857</org_study_id>
    <secondary_id>BUMC-H-27277</secondary_id>
    <nct_id>NCT00790647</nct_id>
  </id_info>
  <brief_title>Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis</brief_title>
  <official_title>Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving melphalan and bortezomib before and after a stem cell transplant stops the
      growth of abnormal cells by stopping them from dividing or killing them. Giving
      colony-stimulating factors and certain chemotherapy drugs, helps stem cells move from the
      bone marrow to the blood so they can be collected and stored. Chemotherapy and monoclonal
      antibody therapy is then given to prepare the bone marrow for the stem cell transplant. The
      stem cells are then returned to the patient to replace the blood-forming cells that were
      destroyed by the chemotherapy.

      PURPOSE: This phase II trial is studying how well giving melphalan together with bortezomib
      followed by stem cell transplant works in treating patients with primary systemic
      amyloidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine if hematologic responses to high-dose melphalan and autologous stem cell
           transplantation increase with addition of bortezomib in the conditioning regimen in
           patients with primary systemic amyloidosis.

      OUTLINE:

        -  Autologous stem cell mobilization and collection: Patients receive filgrastim to
           mobilize stem cells, which are then collected.

        -  Conditioning regimen: Patients receive bortezomib intravenously on days -6, -3, 1, and 4
           and oral high-dose melphalan on days -2 and -1.

        -  Stem cell transplantation: Patients undergo autologous stem cell transplantation on day
           0.

      After completion of study therapy, patients are followed every 6 months for 1 year and
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Hematologic Response</measure>
    <time_frame>one year</time_frame>
    <description>complete and partial hematologic response defined as: Complete response: absence of detectable monoclonal protein in serum and urine, and bone marrow biopsy &lt;5% plasma cells with no clonal predominance of kappa or lambda isotype.
Partial response: any one of the following
For patients with detectable and quantifiable marrow plasmacytosis, a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells.
For patients with a detectable monoclonal peak on serum protein electropheresis or urine protein electropheresis, a reduction in the peak height of 50% or more.
For patients with quantifiable urinary kappa or lambda chain concentration, a reduction in daily light chain excretion (concentration x 24-hr urine volume).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Surviving at 100 Days From Transplant</measure>
    <time_frame>100 Days from transplant date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Surviving at 1 Year</measure>
    <time_frame>one year from transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Surviving at 2 Years</measure>
    <time_frame>2 years from transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplant with Bortezomib and Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection</description>
    <arm_group_label>Stem Cell Transplant with Bortezomib and Melphalan</arm_group_label>
    <other_name>Growth-Colony Stimulating Factor, neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>1.0 mg/m2/dose D -6, D-3, D +1, D + 4</description>
    <arm_group_label>Stem Cell Transplant with Bortezomib and Melphalan</arm_group_label>
    <other_name>velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>100 mg/m2/dose D -2, D -1</description>
    <arm_group_label>Stem Cell Transplant with Bortezomib and Melphalan</arm_group_label>
    <other_name>alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Infusion</intervention_name>
    <description>infusion of previously collected autologous stem cells</description>
    <arm_group_label>Stem Cell Transplant with Bortezomib and Melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary systemic amyloidosis based on the following criteria:

               -  Amyloid light-chain disease

               -  Deposition of amyloid material by congo red stain showing characteristic green
                  birefringence

               -  Monoclonal light chain protein (Bence Jones protein) in the serum or urine,
                  immunohistochemical studies, or serum free light chain assay

               -  Evidence of tissue involvement other than carpal tunnel syndrome (i.e., positive
                  immunohistochemical staining of bone marrow demonstrating clonal plasma cells);
                  tissue amyloid deposits with anti-kappa or anti-lambda anti-serum; evidence for a
                  plasma cell dyscrasia by serum/urine or bone marrow; or overwhelmingly convincing
                  clinical features (e.g., macroglossia) associated with other systemic
                  manifestations

        PATIENT CHARACTERISTICS:

          -  Southwest Oncology Group performance status 0-1

          -  Fertile patients must use effective contraception

          -  Left ventricular ejection fraction ≥ 45% by Echocardiogram within the past 60 days

          -  diffusion capacity of lung for carbon monoxide ≥ 50%

        PRIOR CONCURRENT THERAPY:

          -  Prior chemotherapy with alkylating agent allowed provided there is no morphological or
             cytogenetic evidence of myelodysplastic syndromes

          -  Prior total cumulative dose of oral melphalan &lt; 300 mg

          -  At least 4 weeks since prior cytotoxic therapy and fully recovered

        Exclusion criteria:

          -  No senile, secondary, localized, dialysis-related, or familial amyloidosis

          -  No overt multiple myeloma (&gt; 30% of bone marrow plasmacytosis, extensive [&gt; 2] lytic
             lesions, or hypercalcemia)

          -  Not pregnant or nursing

          -  No myocardial infarction within the past 6 months, congestive heart failure, or
             arrhythmia refractory to therapy

          -  No prior malignancy except for any of the following:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  In situ cervical cancer

               -  Adequately treated stage I or II cancer currently in complete remission

               -  Any cancer from which the patient has been disease-free ≥ 5 years

          -  No advanced (grade 3-4) pre-existing neuropathy

          -  No HIV positivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaishali Sanchorawala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>September 9, 2016</results_first_submitted>
  <results_first_submitted_qc>December 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2017</results_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Vaishali Sanchorawala</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>primary systemic amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SCT With Bortezomib and Melphalan</title>
          <description>Mobilization with Filgrastim Stem Cell Collection (SCC) Bortezomib Melphalan Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days before SCC through day before final SCC
bortezomib: 1.0 mg/m2/dose D –6, D-3, D +1, D + 4
melphalan: 100 mg/m2/dose D –2, D –1
Stem Cell Infusion: infusion of previously collected autologous stem cells</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SCT With Bortezomib and Melphalan</title>
          <description>Mobilization with Filgrastim Stem Cell Collection (SCC) Bortezomib Melphalan Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days before SCC through day before final SCC
bortezomib: 1.0 mg/m2/dose D –6, D-3, D +1, D + 4
melphalan: 100 mg/m2/dose D –2, D –1
Stem Cell Infusion: infusion of previously collected autologous stem cells</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hematologic Response</title>
        <description>complete and partial hematologic response defined as: Complete response: absence of detectable monoclonal protein in serum and urine, and bone marrow biopsy &lt;5% plasma cells with no clonal predominance of kappa or lambda isotype.
Partial response: any one of the following
For patients with detectable and quantifiable marrow plasmacytosis, a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells.
For patients with a detectable monoclonal peak on serum protein electropheresis or urine protein electropheresis, a reduction in the peak height of 50% or more.
For patients with quantifiable urinary kappa or lambda chain concentration, a reduction in daily light chain excretion (concentration x 24-hr urine volume).</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant With Bortezomib and Melphalan</title>
            <description>Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days before Stem Cell Collectionthrough day before final Stem Cell Collection
bortezomib: 1.0 mg/m2/dose D –6, D-3, D +1, D + 4
melphalan: 100 mg/m2/dose D –2, D –1
Stem Cell Infusion: infusion of previously collected autologous stem cells</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematologic Response</title>
          <description>complete and partial hematologic response defined as: Complete response: absence of detectable monoclonal protein in serum and urine, and bone marrow biopsy &lt;5% plasma cells with no clonal predominance of kappa or lambda isotype.
Partial response: any one of the following
For patients with detectable and quantifiable marrow plasmacytosis, a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells.
For patients with a detectable monoclonal peak on serum protein electropheresis or urine protein electropheresis, a reduction in the peak height of 50% or more.
For patients with quantifiable urinary kappa or lambda chain concentration, a reduction in daily light chain excretion (concentration x 24-hr urine volume).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Surviving at 100 Days From Transplant</title>
        <time_frame>100 Days from transplant date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant With Bortezomib and Melphalan</title>
            <description>Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days before Stem Cell Collection through day before final Stem Cell Collection
bortezomib: 1.0 mg/m2/dose D –6, D-3, D +1, D + 4
melphalan: 100 mg/m2/dose D –2, D –1
Stem Cell Infusion: infusion of previously collected autologous stem cells</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Surviving at 100 Days From Transplant</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Surviving at 1 Year</title>
        <time_frame>one year from transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplantation With Bortezomib and Melphalan</title>
            <description>Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days before Stem Cell Collection through day before final Stem Cell Collection
bortezomib: 1.0 mg/m2/dose D –6, D-3, D +1, D + 4
melphalan: 100 mg/m2/dose D –2, D –1
Stem Cell Infusion: infusion of previously collected autologous stem cells</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Surviving at 1 Year</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Surviving at 2 Years</title>
        <time_frame>2 years from transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant With Bortezomib and Melphalan</title>
            <description>Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days before Stem Cell Collectionthrough day before final Stem Cell Collection
bortezomib: 1.0 mg/m2/dose D –6, D-3, D +1, D + 4
melphalan: 100 mg/m2/dose D –2, D –1
Stem Cell Infusion: infusion of previously collected autologous stem cells</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Surviving at 2 Years</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SCT With Bortezomib and Melphalan</title>
          <description>Mobilization with Filgrastim Stem Cell Collection (SCC) Bortezomib Melphalan Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days before SCC through day before final SCC
bortezomib: 1.0 mg/m2/dose D –6, D-3, D +1, D + 4
melphalan: 100 mg/m2/dose D –2, D –1
Stem Cell Infusion: infusion of previously collected autologous stem cells</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (4.0)">pancytopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (4.0)">coagulation</sub_title>
                <description>fibrinogen</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>elevated troponin I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>vomit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (4.0)">fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <description>limbs</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>deconditioning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>increased alkylase phosphate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>decreased phosphate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>deconditioning</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hiccups</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>increased alkylase phosphate</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vaishali Sanchorawala</name_or_title>
      <organization>Boston Medical Center</organization>
      <phone>617-638-8265</phone>
      <email>vaishali.sanchorawala@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

